Handelsbanken Fonder Ab Summit Therapeutics Inc. Transaction History
Handelsbanken Fonder Ab
- $26.2 Billion
- Q4 2024
A detailed history of Handelsbanken Fonder Ab transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Handelsbanken Fonder Ab holds 37,100 shares of SMMT stock, worth $789,117. This represents 0.0% of its overall portfolio holdings.
Number of Shares
37,100
Previous 88,000
57.84%
Holding current value
$789,117
Previous $1.93 Million
65.65%
% of portfolio
0.0%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding SMMT
# of Institutions
230Shares Held
83.1MCall Options Held
1.63MPut Options Held
2.56M-
Baker Bros. Advisors LP New York, NY24.4MShares$520 Million4.83% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$248 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$168 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.56MShares$139 Million0.01% of portfolio
-
State Street Corp Boston, MA5.6MShares$119 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.28B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...